Nicox (FRA:NXOA) Interest Expense : €-1.63 Mil (TTM As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Nicox Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Nicox's interest expense for the six months ended in Dec. 2023 was € -0.75 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was €-1.63 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Nicox's Operating Income for the six months ended in Dec. 2023 was € -9.28 Mil. Nicox's Interest Expense for the six months ended in Dec. 2023 was € -0.75 Mil. Nicox did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Nicox Interest Expense Historical Data

The historical data trend for Nicox's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nicox Interest Expense Chart

Nicox Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

0.87

-2.21

-2.02

-1.63

Nicox Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Interest Expense	Get a 7-Day Free Trial															-1.32	-0.89	-0.74	-0.88	-0.75

Nicox Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-1.63 Mil.

Nicox (FRA:NXOA) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Nicox's Interest Expense for the six months ended in Dec. 2023 was €-0.75 Mil. Its Operating Income for the six months ended in Dec. 2023 was €-9.28 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2023 was €25.15 Mil.

Nicox's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Nicox did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Nicox (FRA:NXOA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nicox SA (FRA:NXOA) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

NICXF:USA ALCOX:France

Address

2405 route des Dolines, Drakkar 2 -Batiment D, Valbonne, Sophia Antipolis, FRA, 06560

Website

https://www.nicox.com

Nicox SA is an international company specializing in ophthalmology developing solutions aimed at maintaining vision and improving eye health. Nicox's program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. It is also conducting research on NCX 1728, a NO-donating phosphodiesterase 5 inhibitor, in retinal diseases. NCX 4251, a patented ophthalmic suspension of fluticasone propionate nanocrystals, for topical ocular application for dry eye, is being developed by Ocumension Therapeutics in China. Nicox generates revenue from VYZULTA in glaucoma and ZERVIATE in allergic conjunctivitis.

Nicox (FRA:NXOA) Headlines

No Headlines